Compare Amgen, Inc. (AMGN) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $118.49. The key difference: Amgen, Inc. pays a 2.77% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals.
| AMGN | QQQE | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $388.16 | $122.72 |
52-Week Low | $271.18 | $96.06 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
QQQE trades at $120.61, up slightly by 0.03% today, with a bullish technical signal driven by strong moving average alignment. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap-weighted peers. Recent news highlights its appeal amid SpaceX's imminent Nasdaq-100 inclusion and as a defensive play in uncertain markets.
The outlook is positive due to structural diversification benefits and potential inflows from index changes. Risks include market volatility and interest rate sensitivity. Analysts favor QQQE for balanced Nasdaq exposure, but its performance remains tied to broader tech sector health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
